As I mentioned before, whatever protocols, treatment modalities, or therapeutic regimens are chosen, I caution the committee again to make sure that those drugs are available and accessible to Canadians and that the drugs are not subject to what we call “manufacturer backorder” or “manufacturer cannot supply”. In terms of the drug distribution channel for manufacturers, whatever we decide, thought and consideration have to be given that the availability of those regimens or drugs is not at the whim of a manufacturer or subject to other influences that could make them unavailable.
On January 27th, 2016. See this statement in context.